Overweight or obesity Nutritional, Metabolic, Endocrine
Conditions
Interventions
Participants will be block randomised to one of three groups, stratified by sex. Randomisation will be performed using https://www.randomizer.org by an independent researcher not involved in recruitme
Sponsors
University of Birmingham
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Males and females between the ages of 65 and 80 years 2. BMI =28 kg/m2, or waist circumference =102 cm for males, and =88 cm for females 3. Generally healthy, assessed via a General Health Questionnaire (GHQ) 4. Weight stable (body mass loss or gain <2 kg in the 6-month period before the study) 5. Able and willing to attend six testing visits and 12 training visits to the University of Birmingham campus
Exclusion criteria
Exclusion criteria: 1. Habitual smoker or vaper 2. Participated in a body mass loss and/or resistance exercise training programme in the 5 years before being enrolled in the study 3. Currently performing regular, structured exercise on >2 days per week 4. Uncontrolled hypertension 5. Cardiovascular or neuromuscular disease 6. Considered unwilling or unable to comply with the study protocol requirements by the research team 7. Regular use of non-steroidal anti-inflammatory drugs (including aspirin) or use of anticoagulants (e.g., warfarin, rivaroxaban) precludes muscle biopsy sampling
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total and regional lean mass measured using DXA at PRE (Day 0), POST (Day 28) and 3-month follow-up (Day 112) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Total and regional fat mass measured using DXA at PRE (Day 0), POST (Day 28) and 3-month follow-up (Day 112) 2. Body mass and height measured at PRE (Day 0), POST (Day 28) and 3-month follow-up (Day 112) 3. Integrated myofibrillar protein synthesis measured using IRMS at PRE (Day 0) and POST (Day 28) 4. Intramuscular protein and gene expression, and lipid content at PRE (Day 0) and POST (Day 28) 5. Biomarkers of metabolic health measured using an automated biochemistry analyser and ELISA at Baseline (Day -7), PRE (Day 0), POST (Day 28) and 3-month follow-up (Day 112) 6. Nitrogen balance measured at Baseline (Day -7), PRE (Day 0), POST (Day 28) and 3-month follow-up (Day 112) 7. Resting energy expenditure measured using indirect calorimetry at PRE (Day 0) and POST (Day 28) 8. Muscle strength measured using resistance exercise machines at PRE (Day 0) and POST (Day 28) 9. Handgrip strength and physical performance measured using handheld dynamometer and SPPB equipment at PRE (Day 0), POST (Day 28) and 3-month follow-up (Day 112) 10. Physical activity monitoring measured using accelerometery at Baseline (Day -7), PRE (Day 0), POST (Day 28) and 3-month follow-up (Day 112) | — |
Countries
England, United Kingdom
Contacts
Public ContactArchie Belfield
Outcome results
None listed